Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aveo Pharmaceuticals has completed its multi-year collaborative agreement with Merck & Co. using its proprietary cancer models to identify and validate tumor maintenance genes which are attractive targets for the development of small molecule oncology agents.
Subscribe to our email newsletter
“Working with Merck in this discovery collaboration, we identified and successfully validated essential tumor maintenance genes suitable for development of small molecule agents in multiple AVEO cancer models,” stated Tuan Ha-Ngoc, president and CEO of AVEO.
Merck says its first collaboration with AVEO led to the discovery of novel candidate drug targets and contributed significantly to its oncology therapeutics discovery efforts. “We look forward to continuing to work with AVEO on our second collaborative effort, which is focused on identifying genetic profiles that correlate with drug response to more effectively guide the clinical development of Merck’s cancer compounds,” said Giulio Draetta, head of oncology basic research.